Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

(2010) N C Tebbutt et al.   BRITISH JOURNAL OF CANCER

HIV-Associated Primary Bone Marrow Hodgkin's Lymphoma: A Distinct Entity?

(2010) Binay K. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Study of Weekly Docetaxel in Combination with Capecitabine in Advanced Gastric and Gastroesophageal Adenocarcinomas

(2010) Shelly S. Lo et al.   ONCOLOGY

The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials

(2009) I. Chau et al.   ANNALS OF ONCOLOGY

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

(2009) Y.-K. Kang et al.   ANNALS OF ONCOLOGY

A Phase II Study of Leucovorin, 5-FU and Docetaxel Combination Chemotherapy in Patients with Inoperable or Postoperative Relapsed Gastric Cancer

(2009) Kwang-Sun Lee et al.   Cancer Research and Treatment

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

(2008) S.-E. Al-Batran et al.   ANNALS OF ONCOLOGY

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE